2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11C.01 Treatment Options for Tumor Progression after Initial Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study

EP.11C.01 Treatment Options for Tumor Progression after Initial Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study

Back to course

Pdf Summary

The study, presented by Yintao Li from Shandong Cancer Hospital and Institute, examines treatment strategies for advanced non-small cell lung cancer (NSCLC) following tumor progression post-immunotherapy. It addresses the ongoing debate on whether continuing immunotherapy is beneficial after progression. In this real-world study, 507 NSCLC patients experiencing progression post-immunotherapy were analyzed to assess survival outcomes based on additional therapy options.<br /><br />The cohort was divided into two groups: those receiving further immunotherapy in combination with other treatments (Immuno-combination group) and those who did not receive additional immunotherapy (No-immuno group). The study focused on progression-free survival (PFS) and overall survival (OS) as key outcomes. <br /><br />Results indicated that the Immuno-combination group demonstrated superior survival outcomes compared to the No-immuno group. Specifically, the 3-month, 6-month, and 12-month PFS were significantly higher for the Immuno-combination group. Similarly, OS rates at 6, 12, and 18 months were also notably better. Subgroup analyses within the Immuno-combination strategy revealed that combining immunotherapy with antiangiogenic therapy resulted in better PFS and OS outcomes compared to combining it with chemotherapy.<br /><br />In conclusion, the findings suggest that patients with NSCLC can still benefit from continued treatment even after tumor progression on initial immunotherapy. Specifically, immunotherapy combined with antiangiogenic therapy appears to be the most effective strategy for extending progression-free and overall survival. This study guides clinical decision-making by highlighting the potential benefits of specific combination therapies in advanced lung cancer management.

Asset Subtitle

Junfeng Zhao

Meta Tag

Speaker Junfeng Zhao

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

NSCLC

immunotherapy

tumor progression

survival outcomes

progression-free survival

overall survival

antiangiogenic therapy

chemotherapy

combination therapy

advanced lung cancer